Carolin Lackner1, Walter Spindelboeck2, Johannes Haybaeck3, Philipp Douschan2, Florian Rainer2, Luigi Terracciano4, Josef Haas5, Andrea Berghold6, Ramon Bataller7, Rudolf E Stauber2. 1. Institute of Pathology, Medical University of Graz, Graz, Austria. Electronic address: karoline.lackner@medunigraz.at. 2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 3. Institute of Pathology, Medical University of Graz, Graz, Austria. 4. Institute of Pathology, University Hospital of Basel, Basel, Switzerland. 5. Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria. 6. Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria. 7. Division of Gastroenterology and Hepatology, Depts of Medicine and Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract
BACKGROUND & AIMS: Few data exist on predictors of long-term prognosis in patients with alcoholic liver disease (ALD). Most studies have only assessed short-term prognosis in patients with advanced ALD. We aimed to assess the prognostic impact of clinical, biochemical and histological parameters on long-term prognosis in patients with early/compensated and decompensated ALD. METHODS: Consecutive patients (n=192) with biopsy-proven liver disease due to alcohol abuse were analyzed retrospectively. Prognostic factors were evaluated in patients with early/compensated ALD (n=60) and in patients with decompensated ALD (clinical decompensation and/or bilirubin >3mg/dl at entry) (n=132). Factors that predict long-term survival were identified using Cox regression models. RESULTS: Liver-related mortality at 5years was 13% in early/compensated and 43% in decompensated ALD. In early/compensated ALD patients, long-term prognosis was determined by fibrosis stage, but not by clinical or biochemical variables. Severe fibrosis (F3/4) was present in 52% and had a major impact on 10-year mortality (F3/4: 45% vs. F0-2: 0%, p<0.001). In contrast, in decompensated patients, a combination of clinical features (sex), biochemical markers of liver failure (bilirubin, international normalized ratio [INR]), and histological features (pericellular fibrosis) predicted long-term survival. During follow-up, abstinence from alcohol was an important predictor of survival in both early/compensated and decompensated ALD. CONCLUSION: Fibrosis stage is the main predictor of long-term survival in patients with early/compensated ALD, while clinical, biochemical and histological parameters predict survival in patients with decompensated disease. Promoting abstinence may improve survival in patients with both early and advanced ALD. LAY SUMMARY: In this study, we evaluated long-term outcome in 192 patients with alcoholic liver disease who underwent liver biopsy: 60 patients with early disease (no symptoms) and 132 patients with advanced disease (jaundice, complications of cirrhosis). Importantly, half of the patients with 'early' disease already had severe fibrosis or cirrhosis on liver histology and dismal outcome (45% mortality at 10years). Abstinence from alcohol improved the prognosis in both early and advanced stages of the disease.
BACKGROUND & AIMS: Few data exist on predictors of long-term prognosis in patients with alcoholic liver disease (ALD). Most studies have only assessed short-term prognosis in patients with advanced ALD. We aimed to assess the prognostic impact of clinical, biochemical and histological parameters on long-term prognosis in patients with early/compensated and decompensated ALD. METHODS: Consecutive patients (n=192) with biopsy-proven liver disease due to alcohol abuse were analyzed retrospectively. Prognostic factors were evaluated in patients with early/compensated ALD (n=60) and in patients with decompensated ALD (clinical decompensation and/or bilirubin >3mg/dl at entry) (n=132). Factors that predict long-term survival were identified using Cox regression models. RESULTS: Liver-related mortality at 5years was 13% in early/compensated and 43% in decompensated ALD. In early/compensated ALDpatients, long-term prognosis was determined by fibrosis stage, but not by clinical or biochemical variables. Severe fibrosis (F3/4) was present in 52% and had a major impact on 10-year mortality (F3/4: 45% vs. F0-2: 0%, p<0.001). In contrast, in decompensated patients, a combination of clinical features (sex), biochemical markers of liver failure (bilirubin, international normalized ratio [INR]), and histological features (pericellular fibrosis) predicted long-term survival. During follow-up, abstinence from alcohol was an important predictor of survival in both early/compensated and decompensated ALD. CONCLUSION:Fibrosis stage is the main predictor of long-term survival in patients with early/compensated ALD, while clinical, biochemical and histological parameters predict survival in patients with decompensated disease. Promoting abstinence may improve survival in patients with both early and advanced ALD. LAY SUMMARY: In this study, we evaluated long-term outcome in 192 patients with alcoholic liver disease who underwent liver biopsy: 60 patients with early disease (no symptoms) and 132 patients with advanced disease (jaundice, complications of cirrhosis). Importantly, half of the patients with 'early' disease already had severe fibrosis or cirrhosis on liver histology and dismal outcome (45% mortality at 10years). Abstinence from alcohol improved the prognosis in both early and advanced stages of the disease.
Authors: Helmut K Seitz; Ramon Bataller; Helena Cortez-Pinto; Bin Gao; Antoni Gual; Carolin Lackner; Philippe Mathurin; Sebastian Mueller; Gyongyi Szabo; Hidekazu Tsukamoto Journal: Nat Rev Dis Primers Date: 2018-08-16 Impact factor: 52.329
Authors: Ashwani K Singal; Ramon Bataller; Joseph Ahn; Patrick S Kamath; Vijay H Shah Journal: Am J Gastroenterol Date: 2018-01-16 Impact factor: 10.864
Authors: Shari Rogal; Ada Youk; Hongwei Zhang; Walid F Gellad; Michael J Fine; Chester B Good; Maggie Chartier; Andrea DiMartini; Timothy Morgan; Ramon Bataller; Kevin L Kraemer Journal: Hepatology Date: 2020-05-22 Impact factor: 17.425
Authors: Margaux Dubois; Amedeo Sciarra; Eric Trépo; Astrid Marot; Joan Saldarriaga; Christophe Moreno; Christine Sempoux; Pierre Deltenre Journal: United European Gastroenterol J Date: 2020-08-10 Impact factor: 4.623